NASDAQ$IRWD
Ironwood Pharmaceuticals Inc. · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported second quarter 2022 results and maintained full year guidance.
Ironwood Pharmaceuticals reported positive momentum in Q2 2022, with LINZESS prescription demand growth and progress in clinical trials. The company ended the quarter with $504 million in cash and cash equivalents and reiterated its 2022 full-year guidance.
- LINZESS EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year.
- GAAP net income was $37 million and adjusted EBITDA was $56 million.
- The company completed its Board of Directors authorized share repurchase program and repaid the remaining principal amount of the 2022 Convertible Notes in cash.
- 2022 guidance of U.S. LINZESS net sales growth of low single digits %, total Ironwood revenue of $420 to $430 million and adjusted EBITDA of >$250 million was reiterated.
Headline financials
Revenue & EPS history
Ironwood Pharmaceuticals · Revenue · Quarterly
$97.2M
Revenue by segment
Ironwood Pharmaceuticals · $71M total across 1 segment · Q1 2020
- LINZESS Collaboration$71M—100.0%
Forward guidance
Ironwood Pharmaceuticals reiterates its 2022 guidance.
Tailwinds
- U.S. LINZESS net sales growth of low single digits %
- Total Ironwood revenue of $420 to $430 million
- Adjusted EBITDA of >$250 million
- Continued focused investments
- Commitment to reaching new patients to drive prescription demand growth moving forward
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-1.0%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-1.2%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+32.8%
Q3 2025
Best reaction
-29.5%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.9% | -15.5% | -31.5% | |
| Q4 2025 | -11.4% | -5.8% | -19.3% | |
| Q3 2025 | +32.8% | +63.5% | +92.2% | |
| Q1 2025 | -4.4% | +0.0% | +5.1% | |
| Q4 2024 | -5.3% | -12.9% | -17.5% | |
| Q3 2024 | -1.6% | -12.9% | -31.9% | |
| Q2 2024 | -29.5% | -25.3% | -25.0% | |
| Q1 2024 | -13.8% | -18.3% | -21.8% | |
| Q4 2023 | -5.6% | -4.0% | -41.6% | |
| Q3 2023 | +5.5% | +5.6% | +13.5% | |
| Q2 2023 | -15.3% | -11.3% | -24.2% | |
| Q1 2023 | +1.5% | -2.4% | +4.9% | |
| Q4 2022 | +5.8% | +3.9% | -7.4% | |
| Q3 2022 | +3.7% | +6.8% | +11.9% | |
| Q2 2022 | +5.9% | +5.6% | -2.9% | |
| Q1 2022 | -3.0% | -8.4% | -9.0% | |
| Q4 2021 | -2.5% | -1.2% | +13.5% | |
| Q3 2021 | +0.4% | -1.2% | -14.6% | |
| Q2 2021 | +3.2% | +4.3% | -1.5% | |
| Q1 2021 | +1.3% | +1.5% | +9.3% | |
| Q4 2020 | -7.0% | -6.6% | +12.3% | |
| Q3 2020 | +4.0% | +12.4% | +16.8% | |
| Q2 2020 | +5.8% | +3.0% | +1.5% | |
| Q1 2020 | -3.2% | +2.5% | -5.3% | |
| Q4 2019 | -3.2% | -2.9% | -18.3% | |
| Q3 2019 | +10.0% | +15.9% | +27.5% | |
| Q2 2019 | +2.6% | -0.8% | -10.0% | |
| Q1 2019 | -9.9% | -12.3% | -7.2% | |
| Q4 2018 | +5.4% | +15.1% | +3.1% | |
| Q3 2018 | -15.6% | -15.9% | -10.3% | |
| Q2 2018 | -1.1% | -1.9% | -1.1% | |
| Q1 2018 | +4.4% | +2.6% | +2.5% | |
| Q4 2017 | +6.0% | +2.4% | +6.0% | |
| Q3 2017 | +6.8% | +1.8% | +16.6% | |
| Q2 2017 | -12.8% | -15.5% | -9.0% | |
| Q1 2017 | +5.2% | +12.9% | +10.5% | |
| Q4 2016 | -1.6% | -4.2% | +0.1% | |
| Q3 2016 | +7.2% | +15.2% | +22.5% | |
| Q2 2016 | -6.0% | -7.7% | -6.9% | |
| Q1 2016 | +9.3% | — | — | |
| Q4 2015 | +3.4% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | -0.1% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | -4.0% | — | — | |
| Q2 2013 | +4.2% | — | — | |
| Q1 2013 | -8.9% | — | — | |
| Q4 2012 | -7.7% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.8% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q1 2012 | -3.5% | — | — | |
| Q4 2011 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q3 2011 | -13.6% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q4 2010 | +0.1% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q1 2010 | -3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro